Zymeworks Inc. is being sued by acquisition target Theravance Biopharma after failing to pay out agreed-upon contingent value rights to shareholders following a 2026 merger. The filing confirms a breach of contract claims regarding the Merger Agreement and subsequent CVR obligations.